Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply.

Chih-Hung Chen

doi:10.1111/apt.15183

Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply.

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

Original language	American English
Pages (from-to)	1106-1107
Journal	Alimentary Pharmacology and Therapeutics
Volume	49
Issue number	8
DOIs	https://doi.org/10.1111/apt.15183
State	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/apt.15183

Cite this

@article{b86ab4be955d4352b958967c06107648,

title = "Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply.",

author = "Chih-Hung Chen",

year = "2019",

doi = "10.1111/apt.15183",

language = "American English",

volume = "49",

pages = "1106--1107",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "John Wiley and Sons Inc",

number = "8",

}

TY - JOUR

T1 - Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply.

AU - Chen, Chih-Hung

PY - 2019

Y1 - 2019

U2 - 10.1111/apt.15183

DO - 10.1111/apt.15183

M3 - Journal Article

C2 - 30920034

SN - 0269-2813

VL - 49

SP - 1106

EP - 1107

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

IS - 8

ER -